Genmap-Pro™
Preclinical decision intelligence for biotech, pharma and investors
Genmap-Pro integrates target biology, molecular evidence, ADME/Tox and translational risk into an independent, decision-ready assessment—before major experimental or investment commitments.
From fragmented evidence to a defensible decision
We assess four decision gates: biological and translational rationale; activity, selectivity and developability; early ADME/Tox and safety liabilities; and the next experiment with the highest information value.
Built for scientific and investment decisions
Biotech CEOs & CSOs
Prioritize programs, challenge scientific assumptions and prepare investor-ready narratives.
Pharma R&D teams
Support target assessment, asset evaluation and early preclinical strategy.
Investors & due diligence teams
Obtain an independent, structured and scientifically grounded view of asset risk.
Academic translational teams
Evaluate therapeutic hypotheses and identify the most relevant next experiments.
Five ways to de-risk a program
- Flash Due Diligence
A rapid 1–2 week assessment to identify early red flags, opportunities and Go / No-Go signals. - Asset Deep Dive
A comprehensive scientific evaluation of a drug discovery asset, integrating biology, activity, selectivity, ADME/Tox, safety and strategic recommendations. - Rare Disease Explorer
A dedicated workflow for rare diseases and poorly documented mechanisms, from biological rationale to candidate prioritization. - Candidate Sprint
An AI-guided generation and evaluation workflow to explore, rank and prioritize new molecular options. - Strategic Partnership
A long-term collaboration model for recurring analyses, dashboards, scientific reviews and strategic decision support.
